Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
10/28/2009 10:21:07 AM
More...
|
New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Santaris Pharma A/S to Establish US Operations
9/16/2009 10:45:15 AM
More...
|
Shire plc (JOBS) Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
8/24/2009 6:21:13 AM
More...
|
Santaris Pharma A/S Interim Report for the Period 1 January to 30 June 2009
7/14/2009 9:46:59 AM
More...
|
Santaris Pharma A/S: LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
6/4/2009 9:05:54 AM
More...
|
Santaris Pharma A/S Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
6/3/2009 9:23:44 AM
More...
|
Santaris Pharma A/S Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals, Inc. (ENZN) Ahead of Schedule
4/27/2009 10:14:15 AM
More...
|
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs Data on LNA-antimiR(R)'s Presented by Santaris Pharma A/S at the American Association for Cancer Research 100th Annual Meeting 2009 in Colorado
4/20/2009 10:29:51 AM
More...
|
Santaris Pharma A/S: Another LNA-based RNA Inhibitor Enters Clinical Trials EZN3042
3/20/2009 8:27:10 AM
More...
|
Wyeth Pharmaceuticals (Pennsylvania) (WYE) and Santaris Pharma A/S Announce Strategic Alliance to Develop RNA-based Medicines; Santaris May Receive Payments of up to $83 Million
1/12/2009 6:43:59 AM
More...
|
|